Cutaneous reactions to novel therapeutics

Area of Science:

• Immunology and Oncology
• Dermatology

Background:

• Biologic agents, like tumor necrosis factor alpha inhibitors, have revolutionized immune-mediated disease treatment.
• Cancer therapies have advanced with agents such as granulocyte macrophage-colony-stimulating factor and kinase inhibitors.
• These potent therapies are associated with a range of toxicities, notably cutaneous reactions.

Purpose of the Study:

• To highlight the significant therapeutic advancements in immune-mediated diseases and cancer.
• To underscore the importance of recognizing treatment-associated cutaneous toxicities.
• To emphasize the clinical value of understanding the histologic features of drug-induced skin reactions.

Main Methods:

• Review of recent advancements in biologic and chemotherapeutic agents.
• Analysis of reported toxicities associated with these novel treatments.
• Focus on the dermatologic manifestations and their histopathology.

Main Results:

• Biologic agents and chemotherapeutics demonstrate potent disease-modifying and anti-cancer effects.
• Cutaneous reactions are a common and significant class of adverse events.
• Histologic examination is crucial for diagnosing and managing these drug-induced skin toxicities.

Conclusions:

• Modern medical treatments offer substantial benefits but necessitate vigilance for side effects.
• Dermatologists and oncologists must be aware of potential skin toxicities from these agents.
• Accurate recognition of skin reactions and their histologic correlates is essential for patient care.